About: Specific elimination of coxsackievirus B3 infected cells with a protein engineered toxin-antitoxin system

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Specific elimination of coxsackievirus B3 infected cells with a protein engineered toxin-antitoxin system Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Specific elimination of coxsackievirus B3 infected cells with a protein engineered toxin-antitoxin system
Creator	Park, Jung-Ho Choi, Wonho Lim, Byung-Kwan Park, Jin-Ho
topic	covid:fff37ff9de7ac14189bacc386448ae96a624f19f#this
source	Medline; PMC
abstract	BACKGROUNDS: Coxsackievirus B3 (CVB3) is a member of the family Picornaviridae, and along with polio-viruses, belongs to the Enterovirus genus. The CVB3 genome is composed single-stranded RNA encoding polyproteins, which are cleaved to individual functional proteins by 2A and 3C proteases proteins which have been targeted for drug development. Here, we showed that protease activity required to activate a toxic protein may be used to prevent viral infection. METHODS: We modified the MazE-MazF antitoxin-toxin system of Escherichia coli to fuse a C-terminal fragment of MazE to the N-terminal end of toxin MazF with a linker having a specific protease cleavage site for CVB3. This fusion protein formed a stable dimer and was capable of inactivating the mRNA interferase activity of MazF which cleaves the ACA sequence in mRNA substrates. RESULTS: The incubation of 2A proteases with the fusion proteins induced cleavage between the MazE and MazF fragments from the fusion proteins; the subsequent release of MazF significantly inhibited virus replication. Additionally, we note that, CVB3 infected HeLa cells quickly died through a MazF toxin mediated effect before virus protein expression. CONCLUSION: These findings suggest that the MazEF fusion protein has a strong potential to be developed as an anti-virus therapy following CVB3 infection.
has issue date	2019-09-30(xsd:dateTime)
bibo:doi	10.1007/s13273-019-0046-4
bibo:pmid	32226459
has license	no-cc
sha1sum (hex)	fff37ff9de7ac14189bacc386448ae96a624f19f
schema:url	https://doi.org/10.1007/s13273-019-0046-4
resource representing a document's title	Specific elimination of coxsackievirus B3 infected cells with a protein engineered toxin-antitoxin system
has PubMed Central identifier	PMC7097453
has PubMed identifier	32226459
schema:publication	Mol Cell Toxicol
resource representing a document's body	covid:fff37ff9de7ac14189bacc386448ae96a624f19f#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/fff37ff9de7ac14189bacc386448ae96a624f19f
is schema:about of	named entity 'Escherichia coli' named entity 'infection' named entity 'toxin' named entity 'replication' named entity 'protein' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software